Protein Degraders Gain Speed as Arvinas Scores Landmark Approval.

Arvinas has achieved a landmark FDA approval for a protein degrader, marking a significant milestone in the protein degradation therapeutic class. The approval represents a major validation of Arvinas' PROTAC platform technology.  

The approval was received ahead of the FDA-assigned PDUFA date of June 5, 2026, suggesting robust clinical trial data supported the regulatory decision. The approval validates Arvinas' protein degradation platform and positions the company as a pioneer in the emerging PROTAC field.  

According to Towards Healthcare, the targeted protein degradation market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 3.94 billion in 2026 to approximately USD 25.36 billion by 2035, representing a compound annual growth rate (CAGR) of 23% from 2026 to 2035. Growth is driven by innovations such as PROTACs and molecular glues, which are expanding the range of druggable proteins with advancements in degradation modalities. Innovations such as PROTACs and molecular glues offer benefits over traditional inhibitors, allowing for the treatment of previously difficult targets.  

Rising Drug Classes Merge Together.  

The PROTAC technology is revolutionizing drug discovery and merging with other drug classes to create a more comprehensive therapeutic approach. This includes the integration of PROTACs with antibody-drug conjugates (ADCs) to enhance the targeting and efficacy of cancer therapies.  

Researchers found that combining PROTACs with ADCs can target not only the disease-causing proteins but also the antibodies that bind to them, leading to more effective and selective treatments. This result to expand the treatment options for various diseases and improved patient outcomes. 

President and CEO of Arvinas Randy Teel said We need to shift over time to where [we’re] best positioned to win, where we can best invest our resources, which may not be in as broad a set of areas as we are now. 

The company is nurturing programs in neurodegeneration and oncology, including its most advanced LRRK2 protein degrader being tested in Parkinson’s disease and a rare brain disorder called progressive supranuclear palsy. 

A recent report by Towards Healthcare highlights that the targeted protein degradation market is witnessing growth due to the growing adoption of precision medicine approaches, which is accelerating the use of targeted protein degradation technologies. With technological advancement and innovations such as PROTACs, molecular glues, and other E3-ligase recruiting technologies, the range of druggable proteins has expanded. The expanding number of research and development activities in this field provides significant market growth opportunities.